Erythropoeisis Stimulating Agents Esas News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8 weeks after treatment compared to placebo. 2. Grade 3-4 treatment-related adverse events were greater in the imetelstat group. Evidence Rating Level: 1 (Excellent) Study Rundown: Patients with red blood cell transfusion-dependent lower-risk myelodysplastic syndromes (LR-MDS) face unmet medical needs when unresponsive to erythropoiesis-stimulating ....

Blood Transfusion , Erythropoeisis Stimulating Agents Esas , Febrile Neutropenia , Myelodysplastic Syndrome , Myelodysplastic Syndromes ,